HIV/AIDS. HIV disease resulting in other viral infections
Conditions
Interventions
Intervention 1: experiment group: Hepatitis B vaccination is perform using Hepavax vaccine 40 microgram for three times with intervals of 0-1-3 months.Levamisole 50 milligram two times a day will b
Prevention
Treatment - Drugs
experiment group: Hepatitis B vaccination is perform using Hepavax vaccine 40 microgram for three times with intervals of 0-1-3 months.Levamisole 50 milligram two times a day will be administered
control group: Hepatitis B vaccination is perform using Hepavax vaccine 40 microgram for three times with intervals of 0-1-3 months.Pelacebo two times a day will be administered form 6 days before
Sponsors
Kermanshah University of Medical Science
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion criteria: HIV infection confirmed by positive double ELISA and WB ;Negative history for HBV infection or vaccination include: Negative tests for HBS-Ag, HBS-Ab abd HBC-Ab; Signature of Informed consent form by participant Exclusion criteria: Refuse the study by participant
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Protective HBS-Ab level which is above 10 IU/ml. Timepoint: with the second and the third times of vaccination and one and three months after that, as well. Method of measurement: HBS-Ab measurement by ELISA method. | — |
Secondary
| Measure | Time frame |
|---|---|
| HBS-Ab titre by IU/ml. Timepoint: with the second and the third times of vaccination and one and three months after that, as well. Method of measurement: tittering of HBS-Ab by ELISA method according to IU/ml. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMoayed Alavian
Baqiyatallah Research Center for Gastroenterology and Liver Diseases
Outcome results
None listed